<DOC>
	<DOCNO>NCT02122770</DOCNO>
	<brief_summary>The primary purpose study assess effect multiple-dose administration fluconazole single-dose intravenous ( IV ) pharmacokinetics ( PK ) MLN4924 ; effect multiple-dose administration itraconazole single-dose IV PK MLN4924 .</brief_summary>
	<brief_title>Effects Fluconazole Itraconazole CYP3A-Mediated Inhibition Pharmacokinetics , Safety , Tolerability MLN4924 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The drug test study MLN4924 . MLN4924 evaluate assess drug-drug interaction ( DDIs ) moderate strong CYP3A inhibitor , fluconazole itraconazole , respectively , patient advance solid tumor . This study look blood concentration MLN4924 relate treatment fluconazole itraconazole . The study enroll approximately 52 patient . In Part A , patient administer MLN4924 via 1-hour ( ± 5 minute ) intravenous ( IV ) infusion combination either fluconazole itraconazole administer orally . After patient complete Part A , opportunity begin treatment Part B . In Part B , patient administer MLN4924 via 1-hour ( ± 5 minute ) IV infusion combination either docetaxel carboplatin + paclitaxel , three would also administer intravenously . This multi-center trial conduct United States . Participation Part A study include screen visit two week treatment ; participation Part B study include 8-week drug washout period ( last dose Part A ) treatment patient experience symptomatic deterioration , progressive disease , treatment discontinue another reason , study stop .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>1 . Male female participant 18 year age old . 2 . Must histologically cytologically confirm metastatic locally advanced incurable solid tumor deem appropriate treatment 1 2 chemotherapy regimen Part B study , progress despite standard therapy , conventional therapy consider effective . The tumor must radiographically clinically evaluable measurable . 3 . Recovered ( ie , ≤ Grade 1 toxicity ) effect prior antineoplastic therapy . 4 . Suitable venous access studyrequired blood sample MLN4924 pharmacokinetic ( PK ) pharmacodynamic assessment . 5 . Eastern Cooperative Oncology Group performance status ( PS ) 0 1 . 6 . Clinical laboratory value specify within 3 day first dose study drug : Hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1,500/mm^3 , support growth factor Platelet count ≥ 100,000/mm^3 Total bilirubin ≤ upper limit normal ( ULN ) Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) ≤ 1.5 x ULN Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) ≤ 2.5 x ULN • For participant treat MLN4924 + docetaxel Part B , AST ALT must ≤ 1.5 x ULN , total bilirubin within normal range . Serum creatinine ≤ 1.2 mg/dL calculated/measured creatinine clearance ≥ 50 mL/minute 7 . Female participant : Are postmenopausal least 1 year screen visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing inform consent four month last dose study drug , Agree practice true abstinence , line prefer usual lifestyle participant . ( Periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Male participant , even surgically sterilize ( ie , status postvasectomy ) , : Agree practice effective barrier contraception entire study treatment period 4 month last dose study drug , Agree practice true abstinence , line prefer usual lifestyle participant . ( Periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method female partner ] withdrawal acceptable method contraception . ) 8 . Voluntary write consent must give performance studyrelated procedure part standard medical care , understand consent may withdraw participant time without prejudice future medical care . 9 . Participants willing refrain donate blood least 90 day final dose MLN4924 ( male participant ) willing refrain donate semen least 4 month final dose MLN4924 . 1 . Prior treatment MLN4924 ; however , prior treatment docetaxel , paclitaxel , carboplatin allow . 2 . Treatment systemic antineoplastic therapy investigational product within 21 day first dose study treatment . 3 . Radiotherapy within 14 day first dose study treatment . 4 . Prior treatment radiation therapy involve ≥ 25 % hematopoietically active bone marrow . 5 . Known hypersensitivity history severe intolerance toxicity studyassigned chemotherapy . Note : History severe hypersensitivity reaction docetaxel ( polysorbate 80based formulation ) participant treat MLN4924 + docetaxel ; history hypersensitivity carboplatin participant treat MLN4924 + carboplatin + paclitaxel ; history severe hypersensitivity paclitaxel ( Cremophorbased formulation ) participant treat MLN4924 + carboplatin + paclitaxel Part B . 6 . Known hypersensitivity/allergy fluconazole itraconazole respective excipients . 7 . Systemic treatment moderate strong cytochrome P450 ( CYP ) CYP3A inhibitor inducer must discontinue least 14 day first dose MLN4924 . Moderate strong CYP3A inhibitor CYP3A inducer permit study . Participants must history amiodarone use 6 month first dose MLN4924 . 8 . Any lifethreatening serious medical psychiatric illness unrelated cancer could , investigator 's opinion , potentially interfere completion treatment accord protocol . 9 . Major surgery within 14 day first dose study treatment . 10 . Active uncontrolled infection severe infectious disease , pneumonia , meningitis , septicemia , methicillinresistant Staphylococcus aureus infection . 11 . Clinically significant central nervous system disease define untreated , progressive , require steroid control symptom . 12 . Known gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerance fluconazole itraconazole include difficulty swallow capsule . 13 . Persistent diarrhea ( ≥ Grade 2 ) last &gt; 3 day within 2 week first dose study treatment . 14 . Known hepatic cirrhosis , hepatitis B surface antigenpositive status , suspect active hepatitis C infection . Note : Participants isolate positive hepatitis B core antibody ( ie , set negative hepatitis B surface antigen negative hepatitis B surface antibody ) must undetectable hepatitis B viral load . 15 . Known human immunodeficiency virus ( HIV ) positive status . 16 . Female participant lactate breastfeed positive serum pregnancy test Screening period positive urine pregnancy test Day 1 first dose study drug . 17 . Uncontrolled high blood pressure ( ie , systolic blood pressure &gt; 180 mm Hg , diastolic blood pressure &gt; 95 mm Hg ) . 18 . Left ventricular ejection fraction &lt; 50 % assessed echocardiogram radionuclide angiography . 19 . Congestive heart failure New York Heart Association Class III IV , Class II recent decompensation require hospitalization within 4 week screen . 20 . Cardiomyopathy history ischemic heart disease . Participants ischemic heart disease acute coronary syndrome ( ACS ) , myocardial infarction ( MI ) , revascularization ( eg , coronary artery bypass graft , stent ) past 6 month exclude . However , participant ischemic heart disease ACS , MI , revascularization great 6 month screen without cardiac symptom may enroll . 21 . Arrhythmia ( eg , history polymorphic ventricular fibrillation torsade de pointes ) . However , participant &lt; Grade 3 atrial fibrillation period least 6 month may enroll . Grade 3 atrial fibrillation define symptomatic incompletely control medically , control device ( eg , pacemaker ) ablation , exclude . Participants paroxysmal atrial fibrillation permit enroll . 22 . Prolonged rate correct QT interval ( QTc ) ≥ 500 millisecond ( msec ) , calculate accord institutional guideline . 23 . Implantable cardioverter defibrillator . 24 . Participants cardiac pacer whose heart rate set fix rate participant concomitant medication may limit increase heart rate response hypotension ( eg , highdose beta blocker ) . 25 . Moderate severe aortic mitral stenosis valvulopathy ( ongoing ) . 26 . Known moderate severe chronic obstructive pulmonary disease ( COPD ) , interstitial lung disease , pulmonary fibrosis , pulmonary arterial hypotension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>